CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
ConditionGVHD,Acute
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorHenry Ford Health System
About this trial
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Eligibility criteria
Qualifiers
Patients >18 year old admitted for allo SCT PB for malignant disease.
Disqualifiers
None
Trial design
Treatments tested in this trial
- blood sample
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov